Trial Profile
Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jul 2023
Price :
$35
*
At a glance
- Drugs Bosentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms COMPASS-2
- Sponsors Actelion Pharmaceuticals
- 24 May 2023 Results of meta analysis (n=1982 from 3 studies NCT01106014 , NCT00660179 and NCT00303459) assessing Outcomes in Patients With Pulmonary Arterial Hypertension (PAH) Associated With Congenital Heart Disease (CHD) Receiving PAH Medication presented at the 119th International Conference of the American Thoracic Society
- 23 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Mar 2014 New trial record